Demonstrates that catch-up vaccination is safe and immunogenic in children receiving sirolimus, suggesting timely immunization is feasible.
= .039). In addition, immune cell subset distributions and post-vaccination cytokine response trajectories were similar between the two groups, indicating preserved vaccine-induced immune competence. Collectively, these findings demonstrate that catch-up vaccination is safe, immunogenic, and well tolerated in children with KHE receiving sirolimus therapy, supporting the feasibility of timely immunization in this immunocompromised pediatric population.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: